1-4 of 4
Alan K. Burnett, MD, FRCPath, FRCP
Close
Sort by
Journal Articles

A Sensitive Risk Score for Directing Treatment in Younger Patients with AML.

Alan K. Burnett, MD, FRCPath, FRCP, Robert K. Hills, MA, MSc, DPhil, Keith Wheatley, DPhil, Anthony H. Goldstone, MRCP, MRCPath, FRCP, Archie G. Prentice, MB, ChB, FRCP, FRCPath, Donald Milligan, MD, FRCP, FRCPath
Journal: Blood
Blood (2006) 108 (11): 18.
https://doi.org/10.1182/blood.V108.11.18.18
Published: 2006
Journal Articles

Treatment of AML in the Elderly: Who Is “Fit” for Intensive Chemotherapy?.

Robert K. Hills, MA, MSc, DPhil, William J. Kell, RCPath,MRCPI, MA, MB, Alan K. Burnett, MD, FRCPath, FRCP
Journal: Blood
Blood (2006) 108 (11): 1974.
https://doi.org/10.1182/blood.V108.11.1974.1974
Published: 2006
Journal Articles

The Feasibility of Combining Daunorubicin, Clofarabine and Gemtuzumab Ozogamicin Is Feasible and Effective. A Pilot Study.

Alan K. Burnett, MD, FRCPath, FRCP, William J. Kell, RCPath,MRCPI, MA, MB, Robert K. Hills, MA,MSc, DPhil, Nigel H. Russell, MD,FRCP,FRCPath, John Yin, MRCP, MRCPath, Ann Hunter, Dominic Culligan
Journal: Blood
Blood (2006) 108 (11): 1950.
https://doi.org/10.1182/blood.V108.11.1950.1950
Published: 2006
Journal Articles

The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.

Alan K. Burnett, MD, FRCPath, FRCP, William J. Kell, MD, Anthony H. Goldstone, DM, Donald Milligan, FRCP, Ann Hunter, FRCP, Archie G. Prentice, FRCP, Nigel H. Russell, MD, Brenda Gibson, FRCP, Keith Wheatley, DPhil, Robert K. Hills, MA, MSc, DPhil
Journal: Blood
Blood (2006) 108 (11): 13.
https://doi.org/10.1182/blood.V108.11.13.13
Published: 2006